JP2024526742A - 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与 - Google Patents

重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与 Download PDF

Info

Publication number
JP2024526742A
JP2024526742A JP2024501754A JP2024501754A JP2024526742A JP 2024526742 A JP2024526742 A JP 2024526742A JP 2024501754 A JP2024501754 A JP 2024501754A JP 2024501754 A JP2024501754 A JP 2024501754A JP 2024526742 A JP2024526742 A JP 2024526742A
Authority
JP
Japan
Prior art keywords
patient
antibody
ravulizumab
treatment
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526742A5 (https=
Inventor
ケンジ フジタ，
ニシ ランパル，
ウェイ－ジアン パン，
カウシック パトラ，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024526742A publication Critical patent/JP2024526742A/ja
Publication of JP2024526742A5 publication Critical patent/JP2024526742A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024501754A 2021-07-14 2022-07-14 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与 Pending JP2024526742A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163221826P 2021-07-14 2021-07-14
US63/221,826 2021-07-14
US202163276271P 2021-11-05 2021-11-05
US63/276,271 2021-11-05
PCT/US2022/037147 WO2023287991A1 (en) 2021-07-14 2022-07-14 Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis

Publications (2)

Publication Number Publication Date
JP2024526742A true JP2024526742A (ja) 2024-07-19
JP2024526742A5 JP2024526742A5 (https=) 2025-07-23

Family

ID=83004487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501754A Pending JP2024526742A (ja) 2021-07-14 2022-07-14 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与

Country Status (4)

Country Link
US (1) US20250154232A1 (https=)
EP (1) EP4370547A1 (https=)
JP (1) JP2024526742A (https=)
WO (1) WO2023287991A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
EP3924380A1 (en) * 2019-02-14 2021-12-22 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis

Also Published As

Publication number Publication date
EP4370547A1 (en) 2024-05-22
US20250154232A1 (en) 2025-05-15
WO2023287991A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US20250243264A1 (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
JP2022512632A (ja) 発作性夜間ヘモグロビン尿症（ｐｎｈ）の処置のための抗ｃ５抗体の皮下投薬及び投与
KR20190012199A (ko) 난치성 전신 중증 근무력증의 치료를 위한 방법
CN116194478A (zh) 皮下（sc）施用抗c5抗体治疗补体相关病症
JP2025084932A (ja) 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体
US20260022164A1 (en) Compositions and methods for the treatment of neuromyelitis optica spectrum disorder
JP2024526742A (ja) 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与
JP2025518796A (ja) 重症筋無力症の治療のための融合ポリペプチドの投薬量及び投与
KR20240004367A (ko) 중증근무력증 치료를 위한 항-cd19 항체의 사용
EA046524B1 (ru) Доза и введение антител к c5 для лечения генерализованной миастении гравис
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
JP2024521474A (ja) 皮膚筋炎（ｄｍ）を治療するための抗ｃ５抗体の投与量及び投与
CN121127494A (zh) 用于治疗自身免疫性疾病的抗cd38抗体
WO2021263056A1 (en) Dosage and administration of anti-c5 antibodies for treatment of amyotrophic lateral sclerosis
EA050729B1 (ru) Антитело к с5 для лечения нейромиелита зрительного нерва со спектральным расстройством
WO2020106724A1 (en) Methods for treatment of refractory generalized myasthenia gravis in pediatric patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714